日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly

奥曲肽缓释剂（CAM2029）治疗肢端肥大症的群体药代动力学分析

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-025-01522-3
Glatard, Anaïs; Friberg-Hietala, Sofia; Keutzer, Lina; Hansson, Anna; Johnsson, Markus; Tiberg, Fredrik
发表日期：2025
文献求助 收藏

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment

耐药结核病治疗中利奈唑胺相关不良事件安全目标的推导和临床应用

期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph16111575
Keutzer, Lina; Mockeliunas, Laurynas; Sturkenboom, Marieke G G; Bolhuis, Mathieu S; Akkerman, Onno W; Simonsson, Ulrika S H
发表日期：2023
文献求助 收藏

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

机器学习和药物计量学在药代动力学数据预测中的应用：以利福平为例阐述其异同及挑战

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics14081530
Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim; Wicha, Sebastian G; Maher-Edwards, Gareth; Vlasakakis, Georgios; Moghaddam, Gita Khalili; Svensson, Elin M; Menden, Michael P; Simonsson, Ulrika S H; On Behalf Of The Unite Tb Consortium
发表日期：2022
文献求助 收藏

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis

基于模型指导的利奈唑胺精准给药治疗耐药结核病

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics14040753
Mockeliunas, Laurynas; Keutzer, Lina; Sturkenboom, Marieke G G; Bolhuis, Mathieu S; Hulskotte, Lotte M G; Akkerman, Onno W; Simonsson, Ulrika S H
治疗耐药
发表日期：2022
文献求助 收藏

A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study

基于模型的贝达喹啉停药后安全有效再引入方案：一项群体药代动力学研究

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12768
Keutzer, Lina; Akhondipour Salehabad, Yasamin; Davies Forsman, Lina; Simonsson, Ulrika S H
发表日期：2022
文献求助 收藏

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review

用于改善结核病治疗的移动健康应用程序：描述性综述

期刊:Jmir Mhealth and Uhealth
影响因子:6.2
doi:10.2196/17246
Keutzer, Lina; Wicha, Sebastian G; Simonsson, Ulrika Sh
发表日期：2020
文献求助 收藏

Medical Device Apps: An Introduction to Regulatory Affairs for Developers

医疗器械应用：面向开发者的监管事务入门

期刊:Jmir Mhealth and Uhealth
影响因子:6.2
doi:10.2196/17567
Keutzer, Lina; Simonsson, Ulrika Sh
发表日期：2020
文献求助 收藏

Establishing Pompe Disease Newborn Screening: The Role of Industry

建立庞贝氏症新生儿筛查：行业的作用

期刊:International Journal of Neonatal Screening
影响因子:4
doi:10.3390/ijns6030055
Keutzer, Joan M
发表日期：2020
文献求助 收藏

VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis

VE-1902-A 是一种具有可逆共价作用机制的直接凝血酶抑制剂，在啮齿动物血栓模型中显示出疗效并能减少出血。

期刊:Thrombosis Research
影响因子:3.4
doi:10.1016/j.thromres.2020.04.020
Sivaraja, Mohanram; Clemens, Daniel M; Sizikov, Sivan; Dash, Subhadra; Xu, Chengpei; Rienzo, Matthew; Yang, Bo; Ryan, Molly; Chattopadhyay, Madhuri; Igoudin, Lev; Chang, Stephanie S; Keutzer, Samuel; Zalicki, Piotr; Estiarte, M Angels; Shiau, Timothy P; Short, Kevin M; Williams, David C; Datta, Anirban; Pozzi, Nicola; Di Cera, Enrico; Gibson, C Michael; Fox, Keith A A; Kita, David B
心血管
发表日期：2020
文献求助 收藏

Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects

在健康受试者中，单次和多次递增剂量给药以及与β-内酰胺类抗生素联合用药后，静脉注射增效剂SPR741的安全性、耐受性、药代动力学和药物相互作用潜力

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/AAC.00892-19
Eckburg, Paul B; Lister, Troy; Walpole, Susannah; Keutzer, Tim; Utley, Luke; Tomayko, John; Kopp, Ellen; Farinola, Nicholas; Coleman, Scott
发表日期：2019
文献求助 收藏